OAA DUO
Occipital and upper cervical application zones, formulated for the cranial dermatome transition.
A two-step topical concept designed around the occipital application area, where cranial and cervical dermatomes meet.
Label QR
Opens the public information page in the reader's language.
https://www.siriamlab.com/qr/oaa-duo
Open patient pageEssential reading. The complete scientific monograph is one click away.
Chapter 01
Product identity
Identification, classification, family, intended use, anatomical region and the documents this record is governed by.
Identification of the record: product identifier, classification, family, intended use, anatomical region and the controlled documents it is governed by.
Documentation metadata+
Chapter 01 — related anatomy
Related documents
Future references
- GTIN / label identifierReservedCommercial identifier reserved for the published label.
Record identification
- Product ID
- SIR-OAA-01
- Family
- OAA DUO
- Region
- Cranial — occipito-atlanto-axial field
- Last update
- 2026-02
Handbook source
Neurodermal modulation of OAA (C0–C2) with a clear EMG response.
- Phase 1: afferent damping
- Phase 2: integration and stabilisation
- Developer
- MT DO, DCP
- Pharmacist
- AVA
- Chapter version
- 1.0
- Product ID
- SIR-OAA-01
The handbook is the scientific master. Every statement rendered on this record originates from this chapter; the platform never creates independent scientific content.
Chapter 02
Executive summary
The record in short: professional summary, patient summary and the sequential treatment model behind it.
The record read in short: professional summary, patient summary and the sequential treatment model behind the formulation.
Documentation metadata+
Chapter 02 — related anatomy
Declared; content in preparation.
Related documents
Future references
- TranslationsReservedExecutive summary in Dutch, French and German.
Executive summary
The reading entry of the record: what the composition is for, in professional and in patient language.
Purpose
OAA DUO exists to give practitioners a clearly delimited application field at the occipital transition, with a two-step texture sequence that supports consistent, reproducible routines.
Clinical goal
Primary anatomical region
occipital
Primary therapeutic objective
Documented cutaneous topical composition for the suboccipital, retroauricular, submandibular and pre-SCM application field.
Professional summary
OAA DUO is documented as a cutaneous topical composition for the head application field. This summary is maintained by the documentation team and updated with each revision of the record.
Patient summary
Occipital and upper cervical application zones, formulated for the cranial dermatome transition.
Keywords
Chapter 03
Anatomy snapshot
The anatomical region of the record and every structure of its application field, resolving into the Neuro Atlas.
The anatomical identity of the record: the region, the segmental levels and the surface territory the formulation is documented for.
Documentation metadata+
Chapter 03 — related anatomy
Related documents
Future references
- 3D Atlas referenceReservedVolumetric reference of the field, prepared for the atlas engine.
- EMG referenceReservedFunctional EMG dataset linked to the segmental levels of this record.
- SRST referenceReservedSegmental reflex surface topography mapping.
Snapshot
Anatomy snapshot
Six metameric expressions per segment — dermatome, myotome, sclerotome, viscerotome, micro-angiotome and neurotome. Individual structures inside an expression open their own illustration plate.
Application zones
Anatomical identity
Primary region
Dermatomes
Peripheral nerves
Plexus
Metamers
Neurocutaneous territories
Body regions
Surface anatomy
- 3D Atlas referenceReservedVolumetric field reference.
- EMG referenceReservedFunctional EMG dataset.
- SRST referenceReservedSegmental reflex surface topography.
Chapter 04
Clinical purpose
Objective, strategy, workflow and the boundaries within which this record is documented.
The clinical objective of the record, its rationale, and the boundaries within which it is documented.
Documentation metadata+
Chapter 04 — related anatomy
Related documents
Future references
- Evidence levelReservedGraded evidence classification per documented statement.
- Clinical casesReservedStructured practitioner observations linked to this record.
Purpose
Why this formulation exists
OAA DUO is documented as a cutaneous topical composition for the head application field. This summary is maintained by the documentation team and updated with each revision of the record.
Why this record exists
OAA DUO exists to give practitioners a clearly delimited application field at the occipital transition, with a two-step texture sequence that supports consistent, reproducible routines.
Neurocutaneous region it was designed for
Occipital neurocutaneous zone
Anatomical interface it addresses
Cranial and occipital surface territories, innervated by branches of the trigeminal and upper cervical nerves.
Clinical philosophy
The occipital field is supplied predominantly by the dorsal ramus of C2 and by C2–C3 contributions travelling with the lesser occipital nerve. This convergence of cranial and cervical territories makes the region anatomically distinctive and well suited to a dedicated surface concept.
- Cutaneous topical composition; the application field is defined by the treating professional.
- Application is documented per session so routines remain comparable over time.
Chapter 05
Application protocol
Timeline, application sites, professional and patient instructions, safety and storage.
Phases, cadence, duration, zone order and the documented application sequence, with practitioner and patient notes.
Documentation metadata+
Chapter 05 — related anatomy
Related documents
Future references
- Printable protocolReservedPrint-ready protocol sheet generated from this record.
Surface
Application zones
The zones listed are possible application locations. The practitioner identifies the exact spot within these possibilities using the SRST (Segmental Reflex Sensitisation Test). Future evaluation will use EMG before and after application.
Suboccipital
Detailed application guidance is in preparation.
Application fieldRetroauricular
Detailed application guidance is in preparation.
Application fieldSubmandibular
Detailed application guidance is in preparation.
Application fieldPre-SCM
Detailed application guidance is in preparation.
Application field
Protocol
Application protocol
Phase 1
Neurodermal release
Week 1–2 · 1–2 applications per day
Until phase 2 is introduced
The first texture is applied thinly on the target zone within the possible application zones, in the official zone order: suboccipital, directly below the hairline; retroauricular, behind the ear; submandibular, from the angle of the mandible towards the chin; and pre-SCM, immediately anterior to the upper portion of the sternocleidomastoid. Zone order stays identical at every session.
SuboccipitalRetroauricularSubmandibularPre-SCMPhase 2
Neurodermal integration
Week 3 evening · from week 4 morning and evening
Until the product is finished
From week 3 phase 2 is added in the evening: phase 1 in the morning on the target zone, phase 2 in the evening on that same target zone. From week 4 — or once phase 1 is finished and phase 2 is also recommended by your therapist — phase 2 is applied on the target zone in the morning and in the evening until the product is finished.
SuboccipitalRetroauricularSubmandibularPre-SCMMaintenance
Continued routine
1–3 sessions per week
Ongoing, reviewed periodically
The sequence is continued at a reduced cadence. Frequency, zones and observations are recorded in the professional log sheet and reviewed at agreed intervals.
SuboccipitalRetroauricularSubmandibularPre-SCM
Zone sequence
- 01Suboccipital
- 02Retroauricular
- 03Submandibular
- 04Pre-SCM
- 01Cleanse and dry the four defined application zones.
- 02Apply step one thinly in the order suboccipital → retroauricular → submandibular → pre-SCM.
- 03Allow two minutes before applying step two over the identical zones.
- 04Use as agreed with your healthcare professional.
Region definition
The four official zones are delimited: suboccipital directly below the hairline, retroauricular behind the ear, submandibular from the angle of the mandible towards the chin, and pre-SCM immediately anterior to the upper sternocleidomastoid.
Sequence
Step one, pause, step two — kept identical across sessions for comparability.
Documentation
Frequency and duration are recorded in the professional log sheet.
OAA protocol (definitive)
Zones
- Pre-auricular
- Mandible
- Temporal
- Retroauricular
Week 1–2
OAA-1 (1–2× per day)
Week 3
Morning: OAA-2 · Evening: OAA-1
Week 4
OAA-2 (1–2× per day)
Week 5
OAA-2 (evening)
On relapse: reintroduce OAA-1 for 3 days.
Chapter 06
Formulation science
The scientific philosophy of the composition: sequential formulation, phase relationship and ingredient rationale.
The composition read as an architecture, with the current formula held read-only and any proposed successor documented alongside it.
Documentation metadata+
Chapter 06 — related anatomy
Declared; content in preparation.
Related documents
Future references
- Ingredient linksReservedEvery constituent resolving to its RM-001 entry.
- Version comparisonReservedSide-by-side comparison of current and proposed composition.
Composition
Formulation architecture
The composition is documented as a map rather than a list. Every constituent is recorded with the function it carries, the reason it is present in this field, how it relates to the rest of the composition and the cutaneous topical formulation category it belongs to.
- 01Aqua base
Aqua
Carrier system
- Functional role
- Carrier phase
- Formulation purpose
- Sets the water phase that determines spreadability across a defined surface field.
- Interaction within the composition
- Holds the humectant fraction in solution and carries the emulsified lipid phase evenly over the zone.
- 02Glycerin
Glycerin
Humectant
- Functional role
- Moisture binding
- Formulation purpose
- Keeps the applied layer supple so the same field can be worked repeatedly without dryness on the skin surface.
- Interaction within the composition
- Balances the emollient fraction: the humectant governs the water phase, the emollient the lipid phase.
- 03Shea butter
Butyrospermum parkii butter
Emollient
- Functional role
- Skin-feel and occlusive body
- Formulation purpose
- Gives the texture enough body to stay on the applied zone rather than running along the hairline.
- Interaction within the composition
- Carries the lipid-soluble antioxidant fraction and slows the evaporation of the water phase.
- 04Panthenol
Panthenol
Conditioning agent
- Functional role
- Surface conditioning
- Formulation purpose
- Documented as a conditioning constituent of the cutaneous topical base; contributes to a smooth, non-tacky finish.
- Interaction within the composition
- Water-soluble; works alongside glycerin in the same phase without altering the emulsion.
- 05Tocopherol
Tocopherol
Antioxidant stabiliser
- Functional role
- Formulation stability
- Formulation purpose
- Protects the lipid fraction over the shelf life of the record so successive batches stay comparable.
- Interaction within the composition
- Dissolved in the shea fraction; stabilises the constituents it is dispersed in rather than acting on the skin.
- 06MSM
Dimethyl sulfone
Sulphur constituent
- Functional role
- Documented constituent of both phases
- Formulation purpose
- Documented constituent of phase 1 and phase 2 of the OAA record; kept at a low level so the texture of both steps stays light and spreadable.
- Interaction within the composition
- Dispersed in a small amount of jojoba before it enters the base, which keeps the powder evenly distributed through the cream.
- 07Rosemary leaf extract
Rosmarinus officinalis leaf extract
Botanical extract
- Functional role
- Aromatic and antioxidant fraction
- Formulation purpose
- Gives phase 1 its recognisable aromatic signature, which practitioners use to distinguish the two textures during a session.
- Interaction within the composition
- Lipid-affine; stabilised by tocopherol and dispersed through the shea fraction.
- 08Magnesium chloride
Magnesium chloride
Mineral salt
- Functional role
- Water-phase mineral constituent
- Formulation purpose
- Documented constituent of the phase 2 water phase; contributes to the lighter, faster-absorbing texture of the integration step.
- Interaction within the composition
- Kept in the aqueous fraction with glycerin; the emulsion is balanced so the salt load does not destabilise the lipid phase.
Reading the map
Constituents are grouped by formulation category: a carrier system that governs spread, a water phase that governs feel, a lipid phase that governs stay-time, and stabilising constituents that keep successive batches comparable. Interactions describe the composition only; no physiological effect is asserted.
Cutaneous topical formulation rationale
The formulation is built for reproducible application on the documented zones: a texture that spreads thinly, a controlled sensory profile and a composition suitable for repeated professional use.
Representative composition overview. The full INCI listing is published in the composition index.
Chapter 07
QR patient information
The label surface, generated from the digital record: what the formulation is, its timeline, application areas, safety and quality assurance.
The label surface of the record, generated from the digital record so patient information can never drift from the documentation.
Documentation metadata+
Chapter 07 — related anatomy
Related documents
Future references
- Printed QRReservedProduction-ready QR code bound to the published version.
Documentation
Downloads
Label
QR resources
Each package carries a QR code that resolves to this documentation record in the reader's language, together with the composition index and the current application protocol. Codes are versioned, so updated documentation reaches practitioners without relabelling.
Resolves to /products/oaa-duo
QR information
- Current QR resolves to
- /products/oaa-duo
- Current version
- 2.1
- Last update
- 2026-02
- Batch number
- OAA-2602
Storage information
Store closed, upright and away from direct sunlight. Storage conditions are documented on the label and repeated here without alteration.
Professional information
Professional reading opens the complete monograph: anatomy, composition architecture, protocol and revision record.
Patient information
Essential reading describes what the composition is, where it is applied and in which order, without clinical interpretation.
- Multilingual QR contentReservedReserved: Dutch, English, French and German resolution of the same record.
Quality system
Version control
The current composition and any proposed successor are documented side by side. Approval and change control are handled outside the platform.
Current formula
- Version
- 2.1
- Revision date
- 2026-02
Reference composition of the flagship record.
Proposed formula
- Version
- 2.2
- Revision date
- 2026-05
Revised emollient fraction proposed for the phase 2 texture; held alongside version 2.1.
QR information
- QR target
- /products/oaa-duo
- Batch reference
- OAA-2602
- Record status
- Documented
The QR code printed on the label resolves to this record. The product page is the single source of truth; printed material never carries content that is not documented here.
Controlled documents →Continue
Explore further
Cutaneous topical formulation. Information is provided for education and professional reference; it is not medical advice and implies no therapeutic effect.
Back to the ecosystem →